What is Allergychoices?
Allergychoices, based in Onalaska, WI, is a specialized provider of sublingual immunotherapy, offering allergy drops designed to help patients manage a broad spectrum of allergies and associated conditions. The company's personalized treatment methodology, known as the La Crosse Method, is supported by extensive clinical validation and research. Allergychoices serves a diverse clientele, including allergists, ENT providers, direct primary care providers, and employers, all seeking effective allergy management solutions. Having successfully treated over 275,000 patients, the company is recognized for its dedication to safety, efficacy, and patient satisfaction in the allergy care market.
How much funding has Allergychoices raised?
Allergychoices has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Allergychoices
PPP
Public-Private Partnership
What's next for Allergychoices?
With a substantial history of patient treatment and a validated therapeutic approach, Allergychoices is well-positioned for continued expansion. The recent strategic investment, alongside its total funding of $150K, suggests a focus on scaling operations, enhancing its sublingual immunotherapy offerings, and potentially broadening its market reach. Future growth may involve further research and development to refine its personalized treatment plans or strategic partnerships to increase accessibility of its allergy drop solutions.
See full Allergychoices company page
